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A major obstacle to the expansion of abnormal cells with significant proliferative potential is the induction of programmed cell death.
Consequently, oncogene-driven hyperproliferation must be associated with apoptosis inhibition to allow malignant outgrowth. The
oncogenic cooperation of N-Myc and Twist-1 in the development of neuroblastoma, the most common and deadly solid tumour of
childhood, perfectly illustrates such a process. N-Myc promotes cell proliferation, whereas Twist-1 counteracts its pro-apoptotic
properties by knocking-down the ARF/p53 pathway. On the basis of numerous recent studies reporting its overexpression in a
variety of human cancers, we discuss in this review the role of Twist-1 as a potent inhibitor of the cell safety programs engaged in
response to an abnormal mitogenic activity.
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The Twist-1 protein (also called Twist) is a highly conserved
transcription factor that belongs to the family of basic helix–
loop–helix (bHLH) proteins (Thisse et al, 1987). bHLH proteins
are structurally and functionally characterised by a conserved
domain containing a stretch of basic amino acids adjacent to two
amphipathic a-helices separated by an interhelical loop. The a-
helices mediate dimerisation with a second bHLH factor, leading to
the formation of a bipartite DNA-binding domain that specifically
binds to hexanucleotide sequences (CANNTG), referred to as E-
boxes. Functional E-boxes are found in the regulatory elements of
many lineage-specific genes. Consistently, bHLH are transcription
factors acting in various differentiation processes, either as
positive or negative regulators, and play key roles in different
developmental events like neurogenesis and myogenesis (for
review see Jan and Jan, 1993). Drosophila twist is a zygotic
developmental gene involved in early mesoderm patterning
(Thisse et al, 1987). It is regulated by a nuclear gradient of the
protein Dorsal, a Rel-containing sequence-specific transcription
factor (Ip et al, 1992), leading to twist expression in the ventral
mesoderm. The encoded Twist protein forms a steep gradient
across the presumptive mesoderm–neuroectoderm border in the
early embryo. Drosophila twist mutants fail to gastrulate indicating
that it is not only necessary for mesoderm differentiation but also
for the morphogenetic movement during gastrulation (Leptin,
1991). Two Twist genes exist in vertebrates, Twist-1 (Twist) and
Twist-2 (formerly known as Dermo-1) (Li et al, 1995). The two
Twist proteins display more than 90% identity in the bHLH and
carboxy-terminal domains (Figure 1). The C-terminal part of the
proteins comprises a ‘Twist box’ which is involved in the
antiosteogenic function of Twist-1 and Twist-2 (Bialek et al,
2004). The N-termini of Twist-1 and Twist-2 are more divergent,
and Twist-2 lacks a glycine-rich region that is present in Twist-1
(Li et al 1995). Twist-1 and Twist-2 have been implicated in the
differentiation of multiple cell lineages including muscle, cartilage
and osteogenic cells. In mice, Twist-1 was shown to be required for
proper development of the head mesenchyme, somites and limb
buds. Mice lacking Twist-1 die at E10.5, whereas mice homozygous
for a Twist-2 null allele show elevated expression of pro-
inflammatory cytokines causing perinatal death (Sosic et al,
2003). Interestingly, mice heterozygous for Twist-1 or Twist-2
mutant alleles are viable, and double heterozygous mutants
phenocopy the severe cachexia seen in twist-2 null mice,
suggesting that Twist-1 and Twist-2 may act redundantly to
control an essential post-natal process (Sosic et al, 2003).
Heterozygosity for Twist-1-null mutations results in a moderate
phenotype including minor skull and limb anomalies. Consis-
tently, germ-line mutations of the coding sequence of the human
Twist-1 gene, leading to haploinsufficiency, have been identified in
the Saethre–Chotzen syndrome (SCS) (acrocephalosyndactyly
type III, ACS III; MIM No.101400). SCS is a hereditary disorder
transmitted as an autosomal dominant trait and characterised by
abnormalities of the limbs, asymmetric head and face, and
premature fusion of cranial sutures (Pantke et al, 1975).
Besides this important role in differentiation, various observa-
tions strongly support a regulatory effect of Twist proteins on
programmed cell death. Notably, Twist-1 haploinsufficiency in SCS
induces calvarial osteoblast apoptosis and Twist-1 homozygous
inactivation in animal models induces massive apoptosis during
mammalian development (Chen and Behringer, 1995). Twist-2
 / 
cells are also dramatically sensitised to cytokine-induced apoptosis
(Sosic et al, 2003). In vitro experiments on mouse embryo
fibroblasts further showed that Twist-1 interferes with the ARF-
p53 regulation pathway, thus blocking c-myc-induced apoptotic
response (Maestro et al, 1999). Moreover, DNazyme-mediated
cleavage of mouse Twist-1 transcripts in mouse mesenchymal
C3H10T1/2 cells increases apoptosis (Hjiantoniou et al, 2003).
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CANCER: THE MODEL OF NEUROBLASTOMA
Neuroblastoma (NB) stands out among paediatric solid tumours
because of its relative frequency, intriguing natural history,
prognostic biologic features, and therapeutic challenges (Brodeur,
2003). Neuroblastoma is considered as an embryonal malignancy
of the postganglionic sympathetic nervous system, generally
arising in the adrenal gland. It is the most common extracranial
paediatric solid tumour, accounting for 7–10% of all childhood
cancers, and the most common neoplasm in infancy. NB is
characterised by a highly heterogeneous clinical behaviour,
ranging from spontaneous regression without treatment to
aggressive therapy-resistant disease. At present, patients are
classified into risk categories on the basis of a combination of
clinical and biological markers. These include age at diagnosis,
stage of disease, histopathology findings, and amplification of the
proto-oncogene N-Myc. N-Myc amplification, observed in about
25% of primary tumours, is strongly associated with rapid tumour
progression and a poor outcome, independently from the stage of
the tumour or the age of the patient, and has thus become an
important factor in clinical decision-making and therapy (Brodeur,
2003). Myc oncoproteins are known examples of cellular
oncoproteins that act both as growth promoting factors and
apoptosis promoters (Evan et al, 1992). Apoptosis is mainly
triggered by the ARF-p53 pathway (Zindy et al, 1998). Interest-
ingly, an in vivo analysis of p53-dependent functions in Myc-
induced lymphomas arising in Em-myc transgenic mice has
indicated that apoptosis is the only p53 effector program that is
selected against during tumour formation (Schmitt et al, 2002),
suggesting that cell cycle checkpoint defects and genomic
instability are by-products of p53 loss. Apoptosis is therefore a
crucial failsafe program to counteract oncogenic Myc activation,
and tumour development requires both hyperproliferation and
prosurvival signalling. Intriguingly, in contrast with most human
cancer types exhibiting an oncogenic Myc activation, primary NBs
rarely display p53 mutations, and deletions or loss of hetero-
zygosity (LOH) at 17p (where p53 maps) are uncommon (Vogan
et al, 1993). This suggests that other defects in p53-dependent
pathways may substitute for intragenic p53 mutations. Although
amplification of the p53-inhibitory MDM2 locus has been
identified in rare cases of NBs and abnormal cytoplasmic p53
localisation has been observed by immunohistochemistry in
undifferentiated NBs (for review see Borriello et al, 2002), the
mechanism of inhibition of p53-dependent apoptosis remains
largely unknown. Interestingly, a deregulation of important
regulators of apoptosis has been reported in NBs, including
overexpression of survivin, a member of the IAP family, and
down-expression of caspase 8. However, no obvious correlation
with N-Myc amplification has been observed (Borriello et al, 2002).
N-Myc-amplified NBs are thus remarkable examples of tumours
displaying a high mitogenic activity, in the presence of a wild-type
p53. With the aim to identify oncogenes or tumour suppressor
genes whose alterations are able to cooperate with N-Myc in NB
development, we performed a genome-wide microarray analysis of
human NBs (Valsesia-Wittmann et al, 2004). This study showed
that N-Myc amplification was constantly associated to the over-
expression of Twist-1. On the basis of previous observations
suggesting an anti-apoptotic activity of Twist-1, we hypothesised
that Twist-1 was able to interfere with the cellular mechanism that
triggers apoptosis in NB cells overexpressing N-Myc. This
hypothesis was first verified by inhibiting endogenous Twist-1
expression in NB cell lines endogenously overexpressing N-Myc
and Twist-1. Such inactivation by RNA interference was sufficient
to promote massive apoptosis. In line with this observation, forced
expression of Twist-1 in non N-Myc amplified NB cells was able to
inhibit p53 response to genotoxic stress. We next demonstrated
that N-Myc and Twist-1 co-expression transforms early-passage
mouse embryo fibroblasts (MEFs), whereas each oncogene
separately fails to do so. The oncogenic cooperation between
N-Myc and Twist-1 was finally confirmed in vivo, the co-expression
of the two oncogenes increasing tumourigenicity of human NB cells
after injection in nude mice. Overall, this study demonstrated the
oncogenic cooperation of two major regulators of embryogenesis,
N-Myc and Twist-1, in the development of NB, supporting the
current hypothesis of an embryonic origin of this tumour. N-Myc
induces cell proliferation, whereas Twist-1 inhibits the ARF-p53
dependent pathway and prevents the apoptotic response normally
triggered by Myc overexpression. By identifying Twist-1 over-
expression as a cause of p53 inactivation, we not only provide a
mechanistic explanation for the rarity of p53 mutations in NBs, but
also show that the collaboration between N-Myc and Twist-1 is
based on escape from natural safeguard response. Nevertheless,
the mechanisms by which Twist-1 compromises p53-response
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Figure 1 Functional domains of human Twist-1 and Twist-2 proteins. The glycine-rich region is specific to Twist-1. The Runx2-binding ‘Twist box’ has
been implicated in the antiosteogenic function of Twist-1 and Twist-2 (Bialek et al, 2004).
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act at different steps of p53-regulation including transcriptional
control and post-translational modifications (Figure 2). Recently,
the group of Raman demonstrated that Twist-1 was able
to physically interact with HOXA5, a potent transactivator of the
p53 promoter, and to modulate its activity (Stasinopoulos et al,
2005). Twist-1 was also found to affect p53 stabilisation by
reducing the expression of the ARF tumour suppressor, an
upstream regulator of p53 (Maestro et al, 1999), and to prevent
post-translational modifications, such as serine 20 phosphoryla-
tion, essential for p53 activation in response to DNA damage
(Stasinopoulos et al, 2005). Finally, Twist-1 could also inhibit p53-
mediated gene transcription through its demonstrated ability to
inhibit p300-mediated acetylation, another post-translational
process involved in the control of p53 activity (Hamamori et al,
1999).
Recent data demonstrated that the anti-apoptotic role of Twist-1
is not restricted to NB cells. Indeed, Twist-1 overexpression was
reported in a variety of solid cancers including breast, prostate and
gastric carcinomas, melanomas, osteosarcomas, rhabdomyosarco-
mas, as well as in Sezary syndrome, a malignancy of CD4þ
memory skin-homing T cells (Maestro et al, 1999; Rosivatz et al,
2002; Hoek et al, 2004; van Doorn et al, 2004; Watanabe et al, 2004;
Entz-Werle et al, 2005; Kwok et al, 2005; Martin et al, 2005). Of
note, Twist-2 has been shown recently to be deregulated in chronic
lymphocytic leukaemia (Raval et al, 2005). Experimental down-
regulation of Twist-1 through small interfering RNA promotes
apoptosis in human breast cancer and melanoma cell lines
(unpublished data). Interestingly, the downregulation of Twist-1
increases cell death sensitivity of PC3 and DU145 prostate cancer
cells, that both lack functional p53, suggesting that Twist-1 might
regulate apoptosis through both p53-dependent and p53-indepen-
dent pathways (Kwok et al, 2005). As mentioned previously, Twist-
2
 /  cells both upregulate TNFa expression and are sensitised to
TNFa-induced apoptosis (Sosic et al, 2003). This phenotype is
recapitulated in Twist-1 and Twist-2 compound heterozygotes
reflecting redundancy and dosage dependence of these genes in
inhibition of cytokine expression (Sosic et al, 2003). In addition to
inactivating p53, Twist proteins may thus also act as NF-kB-
controlled anti-apoptotic factors.
Considering that N-Myc amplified NBs are highly metastatic
tumours and that Twist-1 overexpression in melanomas is
associated to an aggressive phenotype (Hoek et al, 2004), we
hypothesise that the anti-apoptotic activity of Twist-1 is likely to
play a significant role in the metastatic process. Our hypothesis is
strengthened by previous reports demonstrating that abrogation of
p53-mediated apoptosis facilitates experimental metastasis by
promoting the survival of tumour cells in circulation (Nikiforov
et al, 1996). The overexpression of Twist-1 may thus be a selective
advantage for a primary tumour cell to survive in settings of
limited survival signals when contact with the original tumour is
lost. Indeed, besides the necessity to avoid effective immune
clearance and to survive in multiple contexts (local stroma, blood
or lymph, secondary site of expansion), malignant cells have to
override a significant number of barriers to metastasise. Hence, the
metastatic process requires a complex set of cellular functions,
including changes in adhesion, initiation of motility, extracellular
matrix proteolysis, intravasation, extravasation into the surround-
ing tissue, molecular interactions of cancer cells with the
environment of the secondary site, initiation of angiogenesis for
ensuring independent nutrient supply and maintenance of growth
leading to the metastatic colonisation.
TWIST, EMT AND METASTASIS: THE MODEL OF
BREAST CARCINOMA
Although still a subject of controversy (Thompson and Newgreen,
2005; Tarin, 2005), the epithelial–mesenchymal transition (EMT)
is proposed as an important step of carcinoma progression. EMT is
a variant of transdifferentiation and a mechanism for dispersing
cell lineages in vertebrate embryos. It is seen early in the course of
development during gastrulation, and plays a major role during
the formation of the heart, the musculoskeletal system, most
craniofacial structures and the peripheral nervous system. Twist
participates in EMTs during mesoderm differentiation in Droso-
phila and during neural crest migration in vertebrates. Hallmarks
of developmental EMT include derangements of apicobasal
polarity, lack of basal laminal integrity, and cell shape plasticity,
allowing an increased migration capability. These processes are
associated to a switch from E-cadherin (epithelial cadherin) to N-
cadherin (neural cadherin) expression. E-cadherin is a homotypic
cell–cell adhesion molecule which is required for the formation of
epithelia in the embryo. It is then expressed on most epithelial
cells, where it forms the adherens junction and facilitates the
formation of the entire epithelial junctional complex. N-cadherin
typically forms homotypic homophilic interactions, but also
heterotytpic and heterophilic interactions have been described.
In the early embryo, N-cadherin is found in the mesoderm,
whereas in the late embryo it is present in neural tissue, lens and
several other epithelial tissues (Derycke and Bracke, 2004). In the
adult, N-cadherin expression is mainly restricted to neural tissue,
retina, endothelial cells, fibroblasts and myocytes. Because strong
migratory and invasive abilities are also characteristic of meta-
static cells, it has been suggested that epithelial cell-derived
tumours acquire a mesenchymal character during tumour
progression. Indeed, several genes implicated in EMT during
embryogenesis are deregulated during tumorigenesis, including
the zinc-finger proteins Snail, SIP-1 and Slug that act as E-cadherin
repressors (Huber et al, 2005, for review). Loss of E-cadherin-
mediated cell–cell adhesion is a frequent event during tumour cell
invasion and metastasis formation (Heimann et al, 2000).
Consistent with this finding, noninvasive transformed cells in
vitro become invasive upon abolishing E-cadherin function or
expression (Vleminckx et al, 1991). Conversely, transfection of
highly invasive epithelial tumor cell lines by E-cadherin cDNA
totally abrogates their invasiveness potential. Several mechanisms
are found to underlie the loss of E-cadherin function during
tumorigenesis: these include mutational events, mostly in breast
lobular carcinomas, or epigenetic mechanisms such as promoter
hypermethylation or transcriptional repression of the gene by
repressor factors. Conversely, gain of expression of N-cadherin is
frequently observed in carcinomas and its forced expression
promotes motility and metastasis of prostate and breast cancer
cells. Interestingly, Twist has been shown to be essential for the
initiation of Drosophila N-cadherin expression during gastrulation
(Oda et al, 1998), and Twist-1 overexpression is correlated to
abnormal expression of N-cadherin mRNA in human diffuse-type
gastric cancer (Rosivatz et al, 2002). As previously mentioned,
Twist-1
ARF  p53 p53 targets Tumour suppressor
activity
Activated
oncogenes DNA damage 
MDM2
Figure 2 Twist-1 as a potent inhibitor of p53 tumour suppressor activity.
Twist inhibits p53-mediated response to cellular stress (activated
oncogenes or DNA damage) by modulating both ARF expression and
p53 post-translational modifications such as phosphorylation and acetyla-
tion.
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including breast, prostate and gastric carcinomas (Rosivatz et al,
2002; Watanabe et al, 2004; Kwok et al, 2005; Martin et al, 2005).
Although the mechanisms underlying this overexpression remain
unknown, Twist-1 expression has been shown to be induced in
response to Wnt-1 in mouse mammary epithelial cells, suggesting
that it might be regulated by Wnt signalling (Howe et al, 2003).
Recently, by using a mouse mammary tumour model, in which a
set of otherwise isogenic tumour cell populations is able to
complete distinct steps of metastasis when implanted into the
mammary glands of BALB/c mice, the group of R. Weinberg
showed that the murine homologue of Twist-1 was required for
intravasation and metastasis of breast cancer cells in the lung
(Yang et al, 2004). Indeed, inhibition of Twist-1 expression by
RNAi in metastatic cancer cells significantly decreases the
efficiency of lung metastasis from the mammary gland as well as
the number of tumour cells that could be recovered from the
circulation. The same authors also demonstrated that ectopic
expression of Twist-1 leads to molecular and morphological
features associated with an EMT, including induction of cell
motility, loss of E-cadherin-mediated cell–cell adhesion and
activation of mesenchymal markers. Similar observations were
recently reported in androgen-independent prostate cancer cells
(Kwok et al, 2005). The link between Twist-1 and E-Cadherin was
strengthened by the demonstration that Twist-1, directly or
indirectly, causes the transcriptional repression of E-cadherin
through the E-box elements present in its promoter region (Yang
et al, 2004). Nevertheless, the reported observation that Twist-1-
overexpression is more frequent in breast lobular carcinomas than
in breast ductal carcinomas (Yang et al, 2004) is intriguing as more
than 50% of lobular carcinomas have E-cadherin mutations. The
fact that forced expression of E-cadherin is not sufficient to reverse
the process in Twist-1-expressing cells (Yang et al, 2004) further
supports the hypothesis that Twist-1 might modulate several
important processes during cancer development, including inhibi-
tion of cell safeguard programs, alteration of cell–cell adhesion
(through control of E- and N-cadherin expression) and deregula-
tion of differentiation, leading to both cell survival and invasion
capability.
CONCLUDING REMARKS
Over the last year, numerous studies have reported the upregula-
tion of Twist-1 in a variety of human cancers. Functional studies
have indicated that Twist-1 may play a major role in tumour
promotion and progression, by inhibiting differentiation, interfer-
ing with the p53 tumour suppressor pathway and favouring cell
survival, and/or inducing an epithelial–mesenchymal-like transi-
tion. Although further studies required to determine the exact
nature of Twist-1 involvement in a defined cancer type, this novel
identification of a crucial regulator of embryogenesis as an
oncogene supports the view of tumours as corrupt forms of
normal development.
At last, the observation of Twist-1 activation in human cancers
might have important clinical implications, both as a prognostic
and/or predictive factor and as a novel therapeutic target. In
support of the first hypothesis, Twist-1 overexpression was shown,
recently, to be a factor of poor prognosis in melanomas (Hoek
et al, 2004), and Twist-1 forced expression triggers the resistance of
human cancer cells to microtubule agents such as taxol and
vincristine (Wang et al, 2004; Kwok et al, 2005). Furthermore, as
discussed previously, Twist-1 probably inhibits both p53-depen-
dent and p53-independent apoptosis. Consequently, the experi-
mental inactivation of Twist-1 by RNA interference leads to cell
death in a variety of cancer cell lines, including NB, melanoma and
breast cancer lines. Downregulation of Twist-1 by antisense
technology in mouse fibroblasts also increases the sensitivity to
etoposide, a DNA-damaging anticancer drug (Dupont et al, 2001).
Overall, these observations suggest that Twist-1 might be an
interesting therapeutic target for increasing cell sensitivity to drug-
induced apoptosis.
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